Cargando...
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
BACKGROUND: GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d. first approved to treat type 2 diabetes in 2005 have been further developed to yield effective compounds/preparations that have overcome the original problem of rapid elimination (short half-life), initially necessitating short in...
Gardado en:
| Publicado en: | Mol Metab |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Elsevier
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8085572/ https://ncbi.nlm.nih.gov/pubmed/33068776 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molmet.2020.101102 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|